Statistics from Altmetric.com
The interesting work of Zhao et al,1 in the June issue of the journal, recommends the use of a patient-tailored dosing regimen in an attempt to optimise continuous-infusion vancomycin (CIV) therapy in the newborn population.
Despite the increasing use of CIV therapy during the past 10 years in neonates and young infants, the data on pharmacokinetics and dosing regimen of this drug are significantly lacking. Zhao et al1 chose to investigate the results of vancomycin therapeutic drug monitoring under three different regimens and to develop an optimised dosing model with the aim to decrease the number of off-target vancomycin …
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.